Retinitis Pigmentosa
Conditions
Keywords
CNGA1 mutation, AAV2, Gene Therapy, Eye disease
Brief summary
The goal of this phase 1 clinical trial is to learn about the safety and efficacy of a gene therapy, VG901, in patients with a rare disorder of the eye called Retinitis Pigmentosa. The main questions the study aims to answer are: * What is the best tolerated dose and are there any side effects, in particular any inflammatory reactions post drug administration? * Are there any early signs of efficacy on visual function? Participants will be administered a single intravitreal dose of VG901 into the most affected eye through a syringe and followed up for a year to monitor safety and efficacy. There will be two cohorts of participants in this study. Study Cohort 1 will receive the low dose and Study Cohort 2 will receive the high dose as specified in the Protocol.
Interventions
DRUGVG901
Administered as specified in the treatment arm. Study Cohort 1 - Low dose; Study Cohort 2 - High dose Other Names: Gene Therapy (AAV2.NN-CNGA1)
Sponsors
VeonGen Therapeutics GmbH
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
To be eligible for study entry, subjects must satisfy all the following criteria: 1. Able to understand and willing to consent to study participation by a written informed consent 2. Male or female ≥ 18 years of age 3. Clinical diagnosis of RP 4. Confirmed pathogenic, biallelic variants in the CNGA1 gene 5. Ellipsoid zone (EZ) length of the fovea of ≥ 3000 μm in the study eye
Exclusion criteria
Subjects will be excluded from the study if one or more of the following statements are applicable to either eye: 1. Additional interfering ocular conditions which would impact study results (e.g., ocular opacity and advanced cataract, uveitis, amblyopia) 2. History or presence of glaucoma 3. Ocular surgery, intravitreal or subretinal implantation of a medical device (within 6 months of screening) 4. Mutations known to cause inherited retinal disease other than biallelic variants in the CNGA1 gene 5. History of ocular infection with herpes simplex virus 6. History of ocular malignancies 7. History of disorders of the internal retina (e.g., retinal detachment) 8. Patients with uncontrolled diabetes (HbA1c \> 7%) 9. Any other retinopathy due to other diseases - including, but not limited to arterial hypertension, previous vascular retinal occlusion, trauma or acquired inflammatory diseases, contraindication to pharmacological mydriasis (e.g., history of angle block glaucoma), diabetes (diabetic retinopathy including macular oedema) 10. Absence of visual function on the contralateral eye 11. Any damage to the optic nerve 12. Individuals performing any other therapy for RP within 3 months before the study, such as - but not limited to - transcorneal electrostimulation 13. Systemic conditions (e.g., autoimmune disorders) which may affect study participation or outcome measures 14. History of immunodeficiency or other medical conditions which may increase the risk of VG901 administration 15. Systemic illness (e.g., hepatitis or human immunodeficiency virus \[HIV\] infection) or medically relevant abnormal laboratory values (3 x upper limit of normal \[ULN\]) in blood analysis including renal and hepatic function 16. Current, or recent, participation in other study/ or administration of investigational biologic agent within 3 months of Screening; Use of any investigational agent, or systemic corticosteroids, or other immunosuppressive drug(s) within 3 months before Screening 17. History of allergy or sensitivity to any compound used in the study 18. Contraindications to systemic immunosuppression 19. Subjects with increased risk of bleeding (i.e., use of anticoagulants or anti-platelet agents within 7 days before VG901 administration and subjects with international normalized ratio \> 2 or Quick \< 50% or partial thromboplastin time \> 50 seconds, thrombocytopenia, as well as any other known coagulopathy) 20. Subject/partner of childbearing potential unwilling to use adequate contraception for the period between Screening and 30 days after treatment, defined as the period from Screening until 30 days after treatment (defined as administration of therapeutic to the eye) 21. For females of childbearing potential, a positive pregnancy test at Screening or Baseline 22. Females who are breastfeeding 23. Previous receipt of any AAV gene therapy product 24. Any condition which leads the investigator to believe that subject cannot comply with the protocol requirements or that may place the subject at an unacceptable risk from participating
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events (AEs) and Serious Adverse Events (SAEs) | Baseline to Month 12 | Number of Adverse Events (AEs) and Serious Adverse Events (SAEs). Ocular inflammation is defined as an adverse event of special interest (AESI). AESI follow the same reporting requirements as SAE. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pulse rate | Screening to Month 12 | Will be recorded in beats per minute. |
| Blood pressure | Screening to Month 12 | Systolic and diastolic blood pressure will be recorded in mmHg. |
| Body temperature | Screening to Month 12 | Will be recorded in °C. |
| Respiratory rate | Screening to Month 12 | Will be recorded in breaths per minute. |
| Slit lamp examination | Screening to Month 12 | Abnormal examination results of conjunctiva, cornea, sclera, lens, anterior segment, and anterior chamber cells as well as quantification of vitreous inflammation and grading of anterior chamber flare will be recorded. |
| Physical Examination | Screening to Month 12 | A complete physical examination will be done at Screening and at Baseline and then at Month 12. On the other timepoints during the 1-year active follow-up phase, symptom-directed physical examination will be conducted. Abnormal examination results will be recorded. |
| Optical coherence tomography (OCT) | Screening to Month 12 | Abnormal examination results will be recorded. |
| Fundus autofluorescence | Screening to Month 12 | Abnormal examination results will be recorded. |
| Tonometry | Screening to Month 12 | Intraocular Pressure (IOP) will be recorded in mmHg. |
| Adeno-associated virus (AAV) spread | From Baseline until two consecutive samples test negative | As detected by quantitative polymerase chain reaction (qPCR) in peripheral blood, urine, and tear. Recorded in vector copies per µL of fluid DNA. |
| Immunopathology | Baseline to Month 12 | Using specific enzyme-linked immunosorbent assays (ELISA) for humoral antibodies against rAAV2 capsid protein. |
| Fundus biomicroscopy | Screening to Month 12 | Cup-to-Disc (C/D) ratio and abnormal examination results will be recorded. |
Countries
Germany
Contacts
Primary ContactAndrea Rindtorff
Outcome results
None listed